DERM - Earnings call transcript Q2 2023 | Journey Medical Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to Journey Medical's Second Quarter 2023 Financial Results and Corporate Update Conference Call. [Operator Instructions] Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes.

A webcast replay of the call will be available approximately 1 hour after the end of the call for approximately 30 days. I would like now to turn the call over to Mr. the Relations CoreIR, of Blazei company's firm. Investor Matt go ahead, sir. Please

Unknown Executive

participating and conference thank afternoon, in you Good for today's call.

Interim Executive Joining Director at me Maraoui, Joe Srinivas Chief Claude for President, joining Bhatia, Research Q&A team leadership Officer; and Clinical Benesch, Sidgiddi, Therapeutics Officer; Development. Vice from Journey Neal Co-Founder, session Dermatology Medical President will of Corporation's Dr. Chief Clinical Dr. Financial Research. us And are the and be

statements be operational will approvals. among making and management that call, including expectations performance, address, things, statements future the this results, Medical's Journey During regulatory other forward-looking conditions receipt for of financial

Forward-looking statement results statements. actual from involves cause those and risks that may differ materially factors to other

company's in XX-K Journey on the can most periodic performance. it. Today's and information particularly reports in Form the this accompanies statements that filed today Medical filed cautionary measures includes and Medical's these For release refer more to the described evaluating about recently its press Form the financial please useful SEC in with Journey risks, Form call XX-Q, X-K call, conference the that non-GAAP factors be risk believes

prepared should or as results in not information with in isolation accordance consider GAAP. for substitute You a this additional

its this measure non-GAAP For please a reconciliation of comparable to most net GAAP the table financial earnings located release. company's press loss, reconciliation directly see measure, financial in the

Chief Officer call Co-Founder, XXXX. my that required is time-sensitive over any of call pleasure as the Journey occur to turn reflect contains after of is X, revise update Executive circumstances obligation Medical. accurate and August this now information that disclaims or this information Maraoui, to to of President content The law, Except publicly Claude It events to Journey any or as today, by Medical call. only

Claude Maraoui

exciting for everyone quarter Matt. This an conference is corporate our to second afternoon, thanks and for XXXX time Journey call Thanks, and joining update. Good Medical.

will Phase this who III as quarter. significant clinical in with making President for Development, data treatment will Vice no the trials primary seen rosacea Immediately greater our safety recently strong and present for we co rebound endpoints line achieved Sidgiddi, by we has will will announced business commercial quarter secondary this on the DFD-XX Dr. the comments the detail. then by questions. issues. I our a And Our all and and brief our some clinical for Srinivas of review and presentation, results be joined trials second open Research following begin

in slides those benefit following only be who trials. from on used of Phase For III reviewing the call, Dr. the slides, where will call the the are the that data our note the is section those of please Sidgiddi

Oracea of half that pleased written million new second X we for for We Health DFD-XX If annual positive dermatology milestone placebo. these for submitting both to a Phase FDA, prescription demonstrated the a results, peak approximately results significant clinical on globally. by DFD-XX according we positive statistical trials and which superiority with the are community. over treatment and is There III This prescriptions evaluating Journey for of broader Medical Rosacea, the X of million very our potentially were $XXX study approved the of application DFD-XX XXXX. in Symphony in plan has sales data. Based believe drug rosacea potential XXXX on the

involved. Journey collaboration data patients With minocycline in dose the for will paradigm market have suffering becoming treatment the a our program the clinically space. call DFD-XX discuss lowest detail. market. The result opportunity direct the to leader that exceptional Phase of results the investigators the point, Reddy's, oral over to Rosacea the Sidgiddi I has the Dr. on for others market these turn the be between outcomes new We the and meaningful is become discuss follow-up of to on as this Journey. III potential and a the all Medical, been this event DFD-XX success Dr. to of the from like this of to the will more transformational At I strategy in of millions believe potential the approval would

Srinivas Sidgiddi

for to Thank reviewing with conducted which design X have DFD-XX moderate-to-severe Oracea, the Journey you, comments key The Medical Claude. the here the our collaboration presentation detail. randomization line approximately to to with I studies a XXX for study readout. rosacea, in would begin would Xs more from top to III Dr. the also in investor patients like X papulopustular in studies my III supporting slides to like on Xs Phase will Phase DFD-XX. Phase has DFD-XX following by placebo. highlights Reddy's III data investors elements. Each I had website, enrolled refer to

X the patients patients the The XXX to the Thus, not of or trials, in study first were in previous treatments XX any these IGA an washed of and X before study Caucasians, the study medication all entry. Subjects points. All X while end X attributed of in efficacy in patients or adequately the previous MVOR-X had and to ratio grade patients medication starting can colors. medication. The of out XXX approximately approximately were study an XXs XXs at the U.S.A., taking second were study approximately assessed co-primary were in U.S. enrolled to were they of the XXX skin enrolled studies confounding treatment. subjects study be while to of patients on a inflammatory XX and total Germany. Of any lesion MVOR-X approximately white the darker count the seen

The IGA subjects for treatment while between XX.X% for Oracea XX.X% DFD-XX subjects was for for placebo. placebo. of IGA it success proportion Oracea against less in XX.X% treatment success, show total lesion that to the XX.X% both First, was DFD-XX and XX against both count for superior count. results significantly proportion DFD-XX, proportion the statistically total placebo. with placebo in P-values inflammatory DFD-XX, and and lesions weeks treatment MVOR-X, XX.X was Oracea of was for and MVOR-X, DFD-XX, the placebo. The showed XX% were against both The p-value duration. The was IGA DFD-XX second, XX.X% and Oracea was success that for XX.X% MVOR-X. for and lesion for X.XXX placebo for inflammatory Oracea than reduction of in than Oracea were The X.XXX reduction X.XXX less lesions subjects difference the with Oracea treatment for P-values placebo. In for that showed than less and XX.X% X.XXX, DFD-XX

reduction In against placebo. both total were values and placebo. was for inflammatory XX.X count XX.X and The lesions than X.XXX for Oracea DFD-XX XX.X p DFD-XX, lesion for MVOR-X, lesions Oracea lesions for the in less

reduction very seen consistently X [Eridyma] placebo studies both both the across be of with improvement key has DFD-XX quality-of-life the shown can placebo. is Oracea from regards to quality-of-life. of data, X has in dermatology to As life compared and RosQol, DFD-XX both statistically tool dermatology rosacea a also Rosacea-specific significant commonly tools, used endpoints Quality-of-Life outperformed trials. And is against placebo life DFD-XX in demonstrated quality tool has significant DLQI, which quality-of-life the used on of that studies. statistically index in quality general the

it were to pleased more considering has rapid both a and a DFD-XX which is we lesion Finally, is studies. of say reduction shown that IGA on action onset week are very placebo efficacy significant these also therapy X count success achievement or from shown has statistically superior onwards, that

to and and These as be a on results Rosacea it the low was both adverse dose. fiscal of in On in our perceived I to being minocycline the placebo. it standard care of the Thank close to the therapy. It found likely you. the significant studies to significant Claude its event be differentiators second being detail. formulations and safety tolerated brings indicate the to compared with the formulation DFD-XX front, of best-in-class table. Based because safe new capture other also now discuss is possibility the more well to We to launch. upon share rates in the safe will quarter market to hand fixed results back DFD-XX being anticipate

Claude Maraoui

commercial to quarter. for results Sidgiddi. now turn operations Thank I attention second the you, like Dr. our improving in would the our to

throughout discussed key quarter for XX% fiscal for our on to metrics call generating The a non-GAAP surpassed million our adjusted see positive last XXXX. expectations, QX growth our achieve sequential remarkable As was year sequential second to in internal investors, XXXX. net which in over year EBITDA $XX.X this objective to corresponds the revenues gain with continued and revenue,

Some key highlights noteworthy of mentioning.

outstanding way in had million to for and XX% which net of our volume the in product Our fourth QX our priority, net Accutane leading core Zilxi sales net results. in quarterly in XX% is in increase sales is had Qbrexza addition portfolio impressive versus high position versus QX, of with gain XX% which of saw as of and Amzeeq of net led QX and all-time an increase. product million $X.X core QX sales increases a second highest to our of new XX% in sequential $X.X the an $X million currently, their we a XXXX, In $X million third of revenue achieving well. Accutane QX brand. compared

build We these as we expect continue trends to momentum.

of adjusted our combined Our earnings anticipated account that X% and legacy congratulate I'd and commercial like we erosion call which our for Ximino the strategic total sales in XX-K executing our achieving and guidance marketing Targadox plan. Journey calendar non-GAAP see continues and in great XXXX. positive revenue to EBITDA teams for brands, which year for remaining making XXXX. is focused only our QX continue are to strides during towards gave XXXX Exelderm,

on is steadfast SG&A in business successfully over the spend. well to taken becoming this has a expenses in SG&A remain goals. A our and revenue expense not SG&A growth and to in parallel. track organization spend implement optimizing our compared Journey steps necessary million million to entire projected been in We effort by our XXXX note, able of QX year. able more efforts achieving we limiting $XX the to efforts, has XXXX. of key QX Important achieve also $X only were and have example we over Our calendar reduction of reduced this appropriate reduction efficient

to trending XXXX. trend objectives to half We are second of into and certainly continue towards our financial continue this meeting the expect

the am I I'll we that, now for to bank quarter. now that the financial X we pleased entire debt. With announce turn review debt East call facility off paid Finally, to has our second over with will the Bank. results who West have Joe, Journey had

Joseph Benesch

Thank results will and hello, everyone. financial I for now review second the XXXX. you, Claude, quarter

quarter growth to by $XX.X million by year XX% from prior As year to a the year the decrease of $XX.X clinical XX% the from quarter in expenses quarter. The and which the $X.X our efforts, second sales related result or on revenues sales for Claude mainly were the from expense slight is total our net as a XX% decreased combined these XXXX increase due quarter primarily for XX% is from and million first prior marketing quarter the prior SG&A mentioned, product total in project of year million core the second products, the marketing. a and prior were of winds in and of the products: DFD-XX Qbrexza, primarily competition Targadox. prior R&D led products, an for XX% generic lower year our decrease continued driven legacy quarter. These from of lower in products results increased revenues net Ximino decreased unit products volumes X expenses these volumes for combined increase focused quarter. The from down. Targadox, product to These revenues due unit due the by by XXXX. to probably Exelderm, million Amzeeq as reduction emphasis substantially primarily quarter company's $XX.X Accutane, from a reflect our trial to expenses Zilxi, and offset decrease

of this initiative, improve and to efficiencies, of last to our with costs cost During align operational than a XXXX, generated. other headcount minimal The and a we we greater impairment is implemented $XX executed reduction asset. SG&A cost-reduction costs. noncash result the in sales to a test initiative reduce reduction revenues towards connection quarter of we SG&A of recorded cuts. The second initiative reduction the with million a force Claude In reduction marketing expenses XXXX, expenses. loss $X.X intended million being implementing In optimize initiative and is the reduce impact overall to better as mentioned, cost quarter annual designed intangible of cost to this expected

on We that event. Ximino future triggering a constituted asset revision and for our $X.XX the that net determined net results diluted balance outlook XXXX the undiscounted Based of for GAAP resulting on share assess or basic be for $X.X quarter to for the this we to net levels, and cash compared identified sheet forecast product of Ximino's a was common We was per not gross recovered. GAAP net second the and the and the first loss share to per and million Ximino expected amount shareholders the loss XXXX, XXXX. the profit the diluted sales the of analysis share and of of future of $X.X $X.XX projected or lower financial current for revised flows periods. quarter reviewed for $XX.X quarter million in $X.XX and basic or basic cash per diluted carry million revenue revised intangible second Ximino flows indicated

of or adjusted per XXXX share $X.XX quarter share per EBITDA adjusted resulted XXXX non-GAAP first and loss million loss basic for or second $X.X compared diluted quarter diluted the $X.X net million a Our net and for an quarter or of $X.XX EBITDA and to of per $XXX,XXX of second and $X.XX net of for basic basic the of XXXX. an share in EBITDA loss the adjusted diluted

We XXXX, XX, paid December cash At to XX, XXXX, $XX.X $X $XX million to to and and EBITDA our had are way West down becoming our From million of cash in March equivalents million $XX as with and had in burn June term May XXXX, at we on compared cash East in our non-GAAP adjusted At revolver well we a loan XX, equivalents. we XXXX. Bank. in cash cash perspective, XXXX. million $XX million restricted positive cash

Subsequently, further much. in effectively West the we all West debt off $XX East Bank of July terminating Bank term of We, were have voluntarily therefore, West the back East We it no very now the dilution additional to facility. paid West our off Bank. to million entire to entire without you any to East I'll pay And Bank obligations outstanding able Claude. XXXX, turn company. Thank loan East

Claude Maraoui

Joe. call. In discussed today's you, Thank recap like I'd lights summary, on to the

secondary standard The met DFD-XX of filing We results. NDA all DFD-XX endpoints. QX on or ratio. to achieved and XXXX superiority is current in outstanding First, showed treatment primary schedule.

suitable DFD-XX potential data Phase suggest long-term usage. million approved, over Our And if globally. sub-antimicrobial I $XXX has sales

QX were XX% results sales. net our our X over In we of promoted financial XXXX QX Second, from products. rebounded QX, QX. XX% up revenue in core Over

payoff Bank East Third, debt the in happened West full July.

our approval. see in cash through enough confident have ability are to DFD-XX to We

well end team at looking are stage in opportunistic to and portfolio. Plus of III ongoing forward of we XXXX. with Fourth, operational profitability, continuing add clinical to targeting down Phase Phase current we work in our with And look day. DFD-XX and you, third commercial as be R&D finally, by to efforts fifth, successful on have our year our to non-GAAP November. results for we forward our business our completion with out-licensing our its We studies. quarter report Thank this winding is our adjusted look assets product BD continues portfolio both in expense a and sharing commercial The to in III various trials. as good and when progress

Operator

[Operator Instructions]

today first Henry Our question of from Capital. Roth comes Scott

Scott Henry

making long cuts, company but do lot it first a in the the term. I'm of from was to it viable was I instrumental think tough making the sure improvement Tremendous quarter. those

So on DFD-XX do gears, start I'm I team going that questions. commend than with to and the your clock. Shifting I quarter with you

First, when was my correct? cash. would the loan, off assumption paid out of you Is all be that that that restricted

Claude Maraoui

Joe, would please? take to that, you like

Joseph Benesch

Scott, that. books, restricted paid had definitely the of cash Yes, on and was it off we with million $X.XX

Scott Henry

target both? lot revenues expenses do in little year, for loss half, being the you money got some started of or of you quarter. you to your or the work then that by To Okay. make a that, lower second be And you still bit do of in also to higher requires it first expect the of the to a with driven Excellent. have down EBITDA because but positive work

Joseph Benesch

Scott, Claude. Yes. It's

Claude Maraoui

Go ahead, Joe, please.

Joseph Benesch

a be to going of It's little bit both, Scott.

right? So residual May still expenses cuts, in April some still had there second quarter some higher in the the and expenses from So had there.

revenue also be standpoint, third cuts. the from So And to sequentially quarter a better. true show the are going quarter, fourth we expect to

Scott Henry

Okay. Great.

to Now to want shift DFD-XX. I just

you to Does would category? typically what this do comment you us to Could uptake? on to trajectory what peak tend peak sales kind see? it we told take your Or reach sales expect how of You rapid be. be it long

Claude Maraoui

plan Scott. after and a that the few we launching Yes, DFD-XX, get Sure, from in in uptake we on XXXX, approval, hopefully, of months terms early doing FDA.

and quickly looking go to has how going asset approved, sales at up. utilizing the sticking switch which just to hope what package drug that to between of you're market start marketplace, we insert to much DFD-XX. What's into as years numbers, key annual the is we'll the asset peak Oracea FDA oral going as terms very to DFD-XX, using the has to head-to-head candidate, the greater typically, rich In not looking of standard the this habits be potential. be to peak us be over X to change systemic ramp but able We're with the to be of a that this going ability gold to has the this X starts sales in a ability go topical

So prescriptions XX some topical to cover we and give that months, background. call currently ratio, last of market is oral prescribe the million prescribing those Oracea our in just you're X sweet in you XX% doctors right that on written are looking year already that last at and spot. We

Scott Henry

you're topical have In and Oracea. done which just correct. Okay. about topical on maybe I of market, into better orals following And to is up If what percent a offering. topical with so is market very sense the versus the ability that product a expand app we oral well. think get because Rosacea about we acne is oral, that XX% market believe the think I the market, XX%

Claude Maraoui

Yes.

the right percentage. off but can oral size back side. acne of in In you're arena, the get head, about that versus of you It to Rosacea on terms exact I of true top the on the holds my topical the number

topical. So XXX,XXX about last the $X.X year million about and XXX,XXX prescriptions, the Oracea of for prescriptions

So percentages. very close to those

Scott Henry

on balance cash to I'm then get well? question to a right a with sense have sheet. and trying may close Are you balance? time, just you to final you equity, here How of more here Okay. the would a how raising you to are from you And pretty but your consider some probably that down as don't Obviously, at path comfortable raise have it flexible you? are the breakeven comfortable get

Claude Maraoui

with start one, I'll Yes. Yes, Joe. this

you like EBITDA dramatically. cut adjusted $XXX,XXX. said, an far, -- our So at really we've We've second exceptional quarter. losses had

is So throw breakeven away. the a within

So continue we We're raise expect to any be able looking to operations. to whatsoever. with equity not funding

looking debt facilities. are We at

I point Certainly, that being proper allows us Scott. the matter to be would profitable, to of think that now, of is where and ability fact, But where the operationally do. in for all our revenues right as the way through XXXX end SG&A at our go we're of falling, terms a

Operator

Riley. Our next from Kalpit question B. of comes Patel

Kalpit Patel

on Congrats Maybe Phase this the I'll a studies on clearing of couple III asset. Yes. DFD-XX. questions start for with

in You the sense the gets Oracea how studies. both real-world Phase today. of to us obviously the that beat were in placebo reflective patients population a Maybe compared trial the and Oracea enrolled III give

Claude Maraoui

Sure. I'll tell you.

I he to Dr. of Bhatia, think also and we Dr. Sidgiddi talk types investigator patients. perhaps can could Neal follow comments. dermatologist, criteria Sidgiddi take up guest that a And inclusion the of Dr. about and real-world have

Srinivas Sidgiddi

please question that Rosacea. the kind hear great Kalpit. the that kind Could transfer counts of that are the when studies question, they prescribe grades IGA you real-world I'll see at that's an drug. on used, to and much And exclusion Can of oral common that, guys providers explain we have were the me reflective you we of said inclusion The Neal. for Yes. patients to okay? very had Having The a those population baseline criteria these lesion

Neal Bhatia

Bhatia Dr. San I'm the Yes, Journey was I've as of the can. for study. Labs investigators one many I Neal Diego. aside. years worked for Reddy's a as just well with we from Dr. as

that antibiotics the tired commercially, their we to inability They're an metronidazole. downturn past applying of is are in be nor in amount much demise in the year Galderma, dermatologists, Rosacea patients treatments like have the of Soolantra upturn turn, been point oral the in considered already due we of been to like flat. to for Rosacea photosensitivity of to even safe their and the By their branded sales led higher generic But amount seeing of seen of to which of [indiscernible] bad from at that doxycycline. the think effective. And about their I Oracea who or see market. That, contrast, commercially concerned think to I a vehicles hypersensitive. the cover lot those face, support or topical so neither a we've not the of products are doses have

wayside. And lot a minocycline fell until men have now, by the unfortunately, the of

well seeing this come fruition dose So in we to trial. minocycline as of the as saw what

strong I treatment think foothold have gaining spot this in that could as standard. for actually very oral a a

other the resist them to think I otherwise of many are component healthy.

pill orally on minimize to other with something not would and again, medications, treating They're a they, prefer labor topically. involved the

our So fit trial the some of were not for trial a well very ended. for of said want -- were would actually way them They did that pleased turned with market. potential this of things so I go let lot know I patients they the into drug out hands. the out their the to think Rosacea but those

Kalpit Patel

for for I can Are of treatment ratio? an understanding today guess since be Bhatia, have they market give commonly here off-label preserved may more is today, or Dr. used just in less you how us as And the you we Understood. or -- an used Okay. capsules it Rosacea. minocycline

Neal Bhatia

of pathway -- many been mean the of process of family number that lot a without are Rosacea. That's cleaved, cell proteins back, impacts understood too started Yes. that and processes I the the the a me for scientific, lines Oracea. that say years the terms inflammatory whole the it capsaicin getting as of doctor in progressing let different tetracycline get a cascade

no optimal been So for one, an proven both targets. have minocycline because, there's effective at doxycycline and dose bacterial

what or threshold, it's anti-inflammatory the doxycycline it's down there's the is So above the medication, dose. no is at antibiotic But can that to minocycline can antibiotic, dosage. consequence have which which a an the action properties, certain lead an more led road, as of to ratio cultivation whether problem

DFD-XX minocycline you allow the DFD the year it if in it makes that product whatever long, indication work it. way fat the safety of against very used, be will, a -- the comes And will in will Now Rosacea. product similar at directed dosage from again, to this be process will

The long-term studies profile that tells XX on. this everything for can weeks and with drugs, that of us have safety else class goes we we a rely along

serve to not in purpose think systems. see the you do I the and for think your have about treating in work disease, let average something high Rosacea patients, to them co-pay, the well high that's to and just year them their XX-some that the I of So run, end, them process deductible. know old, of treat on not the they back a medication going them office have rather I'd long fine-tune the will

So [indiscernible] I hope that for makes sense you.

Kalpit Patel

the profile formulation release No, Do a it's special advantages believe, tolerability of immediate-release terms just is generic tablets And safety any see extended here that's using capsules? one, minocycline. or this you or of an helpful. versus or I minocycline in profile

Neal Bhatia

natural. compared synthetic a doxycycline, which is minocycline mean, is I to drug

cause So at higher high doxycyclines the kidney and vertigo things doses GI at effects long Minocycline that dose-limited can lupus-like are cause effects and headaches, are more doses. issues and photosensitivity, term immediate. They over distress.

likely issues less this related we to stigma minocycline. long-term chronic to any once that a with were are higher doses see dose, of So

was the absorbed selfish treating than and standpoint, the it unit better a which to on dermatologists and looked a logistics switch minocycline as the why [doxy] it the sending always let's the physicians fat this we'd sound because us is "Well, From doxycycline. better and care nature lot and they drug skin, of at were drug and acne, were who layers and is our always in as Rosacea pilosebaceous primary for middle say, might minocycline, patients acne the of others So a up. by

bit a this. dermatologists of possession that their So hands get they going there's will to be when feel little on

Kalpit Patel

gets this you Dr. opportunity-related patients prescribe maybe use continue here proportion you, drug Rosacea for assuming Got And it. of market last And approved, question to this one what proportion what would drug? Oracea? would If your you

Neal Bhatia

be early Sure. adopter. I'll mean, I I'm an honest,

I are something probably So dermatologists new much a get There I say, minocycline. going going something, it. There be chance are minocycline. flood And get comfortable in with those going be I'm to on to who be be Oracea. to when others hands pretty tied and all everybody not to my with might there's a no, on will who to take fairness, few I

So all to be of bring of mindsets up that will marketing journey those kind all and the that approach way. forward to

As myself, if about problem with would I used process you is that. conferences to I textbooks. an my the and route. about father's on to would speak Rosacea convincing want educator published on your colleagues first approach at get we to no I'm I an Rosacea to talking work call it have the talking than safety efficacious and an And minocycline, oral about here of maybe probably what off ledge rather be know with concerned

Kalpit Patel

Okay.

we of Could in studies erythema How your maybe least of as we Okay. saw trial in improvement significant question those one did the in I And the erythema. believe at Oracea's for day, a studies pivotal the statistically clinical fair itself. both see one company, back for that in here studies? well? X

Claude Maraoui

Sidgiddi, can you take that please? one,

Srinivas Sidgiddi

Sure, Claude.

So end was in from the the the the of out no own studies. while on significance there that a during one Kalpit, FDA days, didn't one both their I did process, NDA Oracea erythema studies, find you're placebo on significance other statistical had those But their right. significance. think the Back review in against show

against important to endpoint, we statistical shown placebo secondary the coming found our back as impact both studies, and significance Now erythema we did study on that studies have for the DFD-XX. an

be to going filing. the our one that's on NDA So key messages of

Neal Bhatia

you investigator an If red. add when is is overall The real as door clinical marker their the is #X that often in looking assessment in to is all concern I less Keep just correct. quick, of and erythema look done of a could that that that's the patient mind, success.

erythema the measures. walk is door at when your papulopustular them assessment when the is the though in one So you of improvement looking more account overall to objective in of grade still grading, the their you're assess even included

So keep less as going in post-inflammatory mind, a getting result if background people or they're the erythema erythema, of the not red are you let know. to

Operator

[Operator session. Instructions] for our now concluded. has The conclude will conference today's this presentation. further attending no With questions, you Thank question-and-answer

You may now disconnect.

Journey Medical (DERM) 8 Aug 232023 Q2 Earnings call transcript